Trial Profile
A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary) ; Brimonidine/timolol (Primary)
- Indications Low tension glaucoma; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Allergan
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.
- 16 Jul 2017 Planned End Date changed from 1 Mar 2018 to 30 Jul 2018.
- 16 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 30 Jul 2018.